Developer docs
API playgroundTry for free, no card

Search company profiles

PegBio

Full company profile

uuid0002edr

Namestring
PegBio
Legal namestring
PegBio Co., Ltd.
Websiteurl
pegbio.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

PegBio Co., Ltd. (派格生物) is a China-based clinical-stage biopharmaceutical company founded in 2008 and publicly listed on the Hong Kong Stock Exchange under ticker hkg:2565. The company is headquartered in Hangzhou, Zhejiang Province (Suite 606, Building 1, Haozhang Mansion, Gongshu District), and is incorporated as a private limited company in China. With 51–100 employees under CEO Michael Xu, PegBio is focused on the in-house discovery and development of innovative therapeutics for chronic metabolic diseases, with its core scientific platform centered on GLP-1 receptor agonist-based therapies. The corporate mission is to bring innovative and effective treatment options to global patients with chronic diseases.

PegBio's product strategy is built around a pipeline of six differentiated drug candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. The lead indications — T2DM and obesity — sit squarely within the GLP-1 receptor agonist class, one of the highest-growth therapeutic categories in metabolic disease. The MASH, OIC, and congenital hyperinsulinemia programs extend the company beyond mainstream GLP-1 applications into liver disease, gastrointestinal side-effect management, and rare metabolic disorders. PegBio cites 'in-house discovery and development,' 'accumulated industry experience,' and 'established R&D capabilities' as the foundation for its differentiated pipeline, and the GLP-1 Receptor Agonist Platform is characterized as the core proprietary technology with a domain specialization differentiator.

As a clinical-stage developer, PegBio has not disclosed commercial product revenue. Its intended go-to-market upon regulatory approval is pharmaceutical distribution through wholesalers, retail pharmacies, and hospital pharmacies, supplemented by potential licensing and royalty arrangements for pipeline candidates. The company is pre-revenue, with capitalization derived from six disclosed private funding rounds between 2011 and 2020 — most notably a $122 million Series E in December 2020 led by Qianhai Fund of Funds, YF Capital, and Yingke Capital — followed by a Hong Kong public listing. No commercial customers, segment-level revenue, or pricing details are disclosed in the available data, consistent with the pre-commercial stage of the business.

Short descriptiontext

PegBio Co., Ltd. (派格生物) is a China-based, Hong Kong-listed clinical-stage biopharmaceutical company developing GLP-1 receptor agonist-based therapeutics across a six-asset pipeline targeting type 2 diabetes, obesity, MASH, opioid-induced constipation, and congenital hyperinsulinemia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GLP-1 receptor agonists, metabolic disorder therapeutics, chronic disease drug development, obesity treatment pipeline, type 2 diabetes therapy
Industry1 code
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals (Metabolic Disease Therapeutics)
Social media profiles1 record
Revenue model1 record
1Pharmaceutical Product Sales
TypeSubscription Recurring
Description

As a clinical-stage biopharmaceutical company, PegBio's primary revenue model is expected to come from product sales of approved therapeutics, combined with potential licensing and royalty arrangements for its drug pipeline candidates targeting metabolic disorders.

pegbio.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PegBio is a clinical-stage biopharmaceutical company that discovers and develops innovative therapeutics for chronic metabolic diseases using a proprietary GLP-1 receptor agonist platform. It maintains a diversified pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia, intended for global commercialization through pharmaceutical distribution channels upon regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Global GLP-1 receptor agonist market projected to grow from US$51.9 billion (2024) to US$137.4 billion by 2030, representing significant market opportunity for innovative metabolic disorder therapeutics
Product overview1 text field

PegBio is a biotechnology company founded in 2008 that focuses on in-house discovery and development of innovative therapies for chronic diseases, with particular emphasis on metabolic disorders. The company has cultivated a diverse pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. The pipeline represents a portfolio of differentiated therapeutics rather than a unified software platform, each addressing specific chronic disease indications.

Product and service5 records
1Type 2 Diabetes Program
CategoryPipeline Candidate
Description

A therapeutic candidate targeting type 2 diabetes mellitus (T2DM), part of PegBio's pipeline of six product candidates focused on metabolic disorders, intended for patients requiring effective blood glucose management.

2Obesity Program
CategoryPipeline Candidate
Description

A therapeutic candidate targeting obesity, one of the six product candidates in PegBio's pipeline addressing chronic metabolic diseases, intended as a next-generation weight loss therapy.

3Metabolic Dysfunction-Associated Steatohepatitis (MASH) Program
CategoryPipeline Candidate
Description

A therapeutic candidate targeting metabolic dysfunction-associated steatohepatitis (MASH), addressing liver fat accumulation, inflammation, and risk of cirrhosis in patients with this chronic metabolic liver disease.

4Opioid-Induced Constipation (OIC) Program
CategoryPipeline Candidate
Description

A therapeutic candidate targeting opioid-induced constipation (OIC), addressing gastrointestinal side effects in patients on opioid pain management therapy.

5Congenital Hyperinsulinemia Program
CategoryPipeline Candidate
Description

A therapeutic candidate targeting congenital hyperinsulinemia, a rare genetic disorder causing excessive insulin production, addressing hypoglycemia and metabolic dysfunction in affected patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Danish clinical-stage biotech developing GLP-1/GLP-2 dual agonists including partnered programs with Sanofi. Comparable metabolic peptide focus with platform overlap on GLP-1 mechanism.

TypeDirect peer
Description

Clinical-stage biotech developing TERN-601, an oral GLP-1 RA for obesity. Comparable mechanism, indication, and development stage to PegBio's obesity program.

TypeDirect peer
Description

Chinese clinical-stage biotech developing ECC5004, an oral small-molecule GLP-1 RA for obesity. Directly comparable as a China-based GLP-1-focused biotech with overlapping metabolic disease targets.

TypeBroad incumbent
Description

Danish pharmaceutical leader with Ozempic, Wegovy, and Rybelsus establishing the GLP-1 standard of care. Major incumbent that defines the competitive landscape PegBio is entering.

TypeRegional player
Description

Korean pharmaceutical company with efpeglenatide and other GLP-1 programs targeting metabolic diseases. Comparable mechanism focus and clinical-stage pipeline, with regional Asian market presence similar to PegBio.

TypeDirect peer
Description

Chinese clinical-stage biotech developing ecoglutide, a long-acting GLP-1 receptor agonist for T2DM and obesity. Comparable pipeline focus, geography, and mechanism approach to PegBio.

TypeDirect peer
Description

Chinese clinical-stage biotech developing mazdutide, a GLP-1/glucagon dual agonist for T2DM and obesity. Directly comparable to PegBio as a Chinese biotech pursuing GLP-1-based metabolic therapeutics with similar indication focus and development stage.

TypeDirect peer
Description

Clinical-stage US biotech developing GSBR-1290, an oral GLP-1 RA for obesity and T2DM. Highly comparable mechanism focus and clinical-stage profile to PegBio.

TypeDirect peer
Description

Clinical-stage biotech developing injectable and oral GLP-1 RAs for obesity. Directly comparable mechanism focus and clinical-stage profile to PegBio's lead obesity asset.

TypeBroad incumbent
Description

US pharmaceutical leader with Mounjaro and Zepbound (tirzepatide) setting efficacy benchmarks in obesity and T2DM. Major incumbent shaping GLP-1 competitive dynamics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PegBio

Biopharmaceuticals (Metabolic Disease Therapeutics)pegbio.com

PegBio Co., Ltd. (派格生物) is a China-based, Hong Kong-listed clinical-stage biopharmaceutical company developing GLP-1 receptor agonist-based therapeutics across a six-asset pipeline targeting type 2 diabetes, obesity, MASH, opioid-induced constipation, and congenital hyperinsulinemia.

What PegBio does

PegBio Co., Ltd. (派格生物) is a China-based clinical-stage biopharmaceutical company founded in 2008 and publicly listed on the Hong Kong Stock Exchange under ticker hkg:2565. The company is headquartered in Hangzhou, Zhejiang Province (Suite 606, Building 1, Haozhang Mansion, Gongshu District), and is incorporated as a private limited company in China. With 51–100 employees under CEO Michael Xu, PegBio is focused on the in-house discovery and development of innovative therapeutics for chronic metabolic diseases, with its core scientific platform centered on GLP-1 receptor agonist-based therapies. The corporate mission is to bring innovative and effective treatment options to global patients with chronic diseases.

PegBio's product strategy is built around a pipeline of six differentiated drug candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. The lead indications — T2DM and obesity — sit squarely within the GLP-1 receptor agonist class, one of the highest-growth therapeutic categories in metabolic disease. The MASH, OIC, and congenital hyperinsulinemia programs extend the company beyond mainstream GLP-1 applications into liver disease, gastrointestinal side-effect management, and rare metabolic disorders. PegBio cites 'in-house discovery and development,' 'accumulated industry experience,' and 'established R&D capabilities' as the foundation for its differentiated pipeline, and the GLP-1 Receptor Agonist Platform is characterized as the core proprietary technology with a domain specialization differentiator.

As a clinical-stage developer, PegBio has not disclosed commercial product revenue. Its intended go-to-market upon regulatory approval is pharmaceutical distribution through wholesalers, retail pharmacies, and hospital pharmacies, supplemented by potential licensing and royalty arrangements for pipeline candidates. The company is pre-revenue, with capitalization derived from six disclosed private funding rounds between 2011 and 2020 — most notably a $122 million Series E in December 2020 led by Qianhai Fund of Funds, YF Capital, and Yingke Capital — followed by a Hong Kong public listing. No commercial customers, segment-level revenue, or pricing details are disclosed in the available data, consistent with the pre-commercial stage of the business.

PegBio firmographics

Firmographics
Name
PegBio
Legal name
PegBio Co., Ltd.
Website
https://pegbio.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
PegBio Co., Ltd. (派格生物) is a China-based, Hong Kong-listed clinical-stage biopharmaceutical company developing GLP-1 receptor agonist-based therapeutics across a six-asset pipeline targeting type 2 diabetes, obesity, MASH, opioid-induced constipation, and congenital hyperinsulinemia.
Ownership category
akta.pro rank

PegBio industry classification

Industry
Product category
Biopharmaceuticals (Metabolic Disease Therapeutics)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • GLP-1 receptor agonists
  • Metabolic disorder therapeutics
  • Chronic disease drug development
  • Obesity treatment pipeline
  • Type 2 diabetes therapy

Where PegBio is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices1 record

Markets served

PegBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: As a clinical-stage biopharmaceutical company, PegBio's primary revenue model is expected to come from product sales of approved therapeutics, combined with potential licensing and royalty arrangements for its drug pipeline candidates targeting metabolic disorders.

Distribution channels1 record

Marketing channels2 records

PegBio product offering

Product offering

Core offering

PegBio is a clinical-stage biopharmaceutical company that discovers and develops innovative therapeutics for chronic metabolic diseases using a proprietary GLP-1 receptor agonist platform. It maintains a diversified pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia, intended for global commercialization through pharmaceutical distribution channels upon regulatory approval.

Product overview

PegBio is a biotechnology company founded in 2008 that focuses on in-house discovery and development of innovative therapies for chronic diseases, with particular emphasis on metabolic disorders. The company has cultivated a diverse pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. The pipeline represents a portfolio of differentiated therapeutics rather than a unified software platform, each addressing specific chronic disease indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Type 2 Diabetes Program A therapeutic candidate targeting type 2 diabetes mellitus (T2DM), part of PegBio's pipeline of six product candidates focused on metabolic disorders, intended for patients requiring effective blood glucose management.
  • Obesity Program A therapeutic candidate targeting obesity, one of the six product candidates in PegBio's pipeline addressing chronic metabolic diseases, intended as a next-generation weight loss therapy.
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH) Program A therapeutic candidate targeting metabolic dysfunction-associated steatohepatitis (MASH), addressing liver fat accumulation, inflammation, and risk of cirrhosis in patients with this chronic metabolic liver disease.
  • Opioid-Induced Constipation (OIC) Program A therapeutic candidate targeting opioid-induced constipation (OIC), addressing gastrointestinal side effects in patients on opioid pain management therapy.
  • Congenital Hyperinsulinemia Program A therapeutic candidate targeting congenital hyperinsulinemia, a rare genetic disorder causing excessive insulin production, addressing hypoglycemia and metabolic dysfunction in affected patients.

Quantifiable outcome

  • Global GLP-1 receptor agonist market projected to grow from US$51.9 billion (2024) to US$137.4 billion by 2030, representing significant market opportunity for innovative metabolic disorder therapeutics

Companies that use PegBio

Customer profile

Segments5 records

Ideal customer profiles2 records

PegBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

PegBio partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

PegBio competitors and assessment

Company assessment

Emerging players

  • Zealand Pharma: Danish clinical-stage biotech developing GLP-1/GLP-2 dual agonists including partnered programs with Sanofi. Comparable metabolic peptide focus with platform overlap on GLP-1 mechanism.

Direct peers

  • Terns Pharmaceuticals: Clinical-stage biotech developing TERN-601, an oral GLP-1 RA for obesity. Comparable mechanism, indication, and development stage to PegBio's obesity program.
  • Eccogene: Chinese clinical-stage biotech developing ECC5004, an oral small-molecule GLP-1 RA for obesity. Directly comparable as a China-based GLP-1-focused biotech with overlapping metabolic disease targets.
  • Sciwind Biosciences: Chinese clinical-stage biotech developing ecoglutide, a long-acting GLP-1 receptor agonist for T2DM and obesity. Comparable pipeline focus, geography, and mechanism approach to PegBio.
  • Innovent Biologics: Chinese clinical-stage biotech developing mazdutide, a GLP-1/glucagon dual agonist for T2DM and obesity. Directly comparable to PegBio as a Chinese biotech pursuing GLP-1-based metabolic therapeutics with similar indication focus and development stage.
  • Structure Therapeutics: Clinical-stage US biotech developing GSBR-1290, an oral GLP-1 RA for obesity and T2DM. Highly comparable mechanism focus and clinical-stage profile to PegBio.
  • Kailera Therapeutics: Clinical-stage biotech developing injectable and oral GLP-1 RAs for obesity. Directly comparable mechanism focus and clinical-stage profile to PegBio's lead obesity asset.

Broad incumbents

  • Novo Nordisk: Danish pharmaceutical leader with Ozempic, Wegovy, and Rybelsus establishing the GLP-1 standard of care. Major incumbent that defines the competitive landscape PegBio is entering.
  • Eli Lilly: US pharmaceutical leader with Mounjaro and Zepbound (tirzepatide) setting efficacy benchmarks in obesity and T2DM. Major incumbent shaping GLP-1 competitive dynamics.

Regional players

  • Hanmi Pharmaceutical: Korean pharmaceutical company with efpeglenatide and other GLP-1 programs targeting metabolic diseases. Comparable mechanism focus and clinical-stage pipeline, with regional Asian market presence similar to PegBio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

PegBio social profiles

Digital presence

PegBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PegBio leadership team

Management profile

Number of profiles

Profiles1 record

PegBio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PegBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PegBio

What does PegBio do?

PegBio is a clinical-stage biopharmaceutical company that discovers and develops innovative therapeutics for chronic metabolic diseases using a proprietary GLP-1 receptor agonist platform. It maintains a diversified pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia, intended for global commercialization through pharmaceutical distribution channels upon regulatory approval.

Is PegBio a public or private company?

PegBio is a private company. It is classified as public and is currently operating.

When was PegBio founded?

PegBio was founded in 2008. It employs 1 to 10 people.

Where is PegBio based?

PegBio is headquartered in Suzhou, China, in the Asia region.

How does PegBio make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are PegBio's main competitors?

Zealand Pharma is listed as an emerging player. Direct peers are Terns Pharmaceuticals, Eccogene, Sciwind Biosciences, Innovent Biologics, Structure Therapeutics and Kailera Therapeutics. Broad incumbents are Novo Nordisk and Eli Lilly. Hanmi Pharmaceutical is listed as a regional player.

Does PegBio have an API?

No public API is recorded for PegBio.

What industry is PegBio in?

PegBio's product category is Biopharmaceuticals (Metabolic Disease Therapeutics). Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPegBio Raises HK$ 80.04 Million in Share PlacementPegBio completed a share placement on November 10, 2026, issuing 26,813,000 new H shares at HKD 2.985 each, raising HKD 80.04 million gross and HKD 77.16 million net. The new shares represent 6.42% of enlarged share capital, with proceeds allocated to pipeline R&D, loan repayment, and working capital.The future of tradingPegBio Co To Place Aggregate Of 26.8 Million SharesPegBio Co Ltd will place an aggregate of 26.8 million shares at HK$2.985 per share. The announcement was made by the company, with no further details provided on the purpose or timing of the placement.AInvestLexaria Bioscience Corp - enters a material transfer agreement with PegBioLexaria Bioscience Corp has entered into a material transfer agreement with PegBio. The article provides no further details regarding the scope, financial terms, or strategic implications of this partnership. This announcement serves as a routine corporate update regarding the company's operational activities.The Pharma LetterRani links with PegBio to grow oral obesity pipelineUSA-based clinical-stage biotherapeutics firm Rani Therapeutics has entered a research and development collaboration with Chinese metabolic disease specialist PegBio to reformulate several of PegBio's obesity and metabolic drug candidates for oral delivery using Rani's RaniPill capsule technology. The preclinical collaboration covers multiple molecules from PegBio's portfolio, with the stated goal of advancing the strongest performers into clinical development. No binding licensing, commercialization, or financial terms were disclosed for the partnership.Longevity.TechnologyRani Therapeutics, PegBio to explore oral obesity candidatesRani Therapeutics has entered an R&D collaboration with PegBio to evaluate oral delivery of multiple obesity and metabolic disease molecules using Rani's RaniPill platform. Under the agreement, the companies will conduct preclinical development of RaniPill formulations for selected PegBio molecules, with the goal of advancing the most promising candidates into clinical development. The collaboration expands Rani Therapeutics' obesity franchise beyond existing programs, including RT-114, a GLP-1/GLP-2 dual agonist currently in Phase 1 being developed with ProGen.YicaiglobalChina's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani TherapeuticsPegBio, a Chinese drugmaker based in Hangzhou, signed a three-year memorandum of understanding with Nasdaq-listed Rani Therapeutics on July 8 to develop oral formulations for obesity and metabolic disease drugs using Rani's proprietary RaniPill delivery platform. The partnership will involve preclinical development and systematic platform-wide evaluations of multiple novel therapeutic candidates from PegBio's pipeline, with plans to explore joint research, manufacturing, and commercialization outside China. PegBio's shares surged 28.8 percent to HKD7.12 following the announcement, reflecting market enthusiasm for the collaboration targeting the high-growth obesity and metabolic disorder space.AInvestPegBio: collaboration with Nasdaq-listed Rani TherapeuticsRani Therapeutics has announced a research collaboration with PegBio Co., Ltd. to develop oral formulations of obesity and metabolic disease molecules using Rani's proprietary RaniPill® platform. The partnership will focus on preclinical development of multiple candidates from PegBio's pipeline, with the goal of advancing promising molecules into clinical trials. The collaboration is expected to expand Rani's obesity franchise beyond its existing programs, including RT-114 and preclinical semaglutide studies.BioSpaceRani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel CandidatesRani Therapeutics announced a research and development collaboration with PegBio to explore oral delivery of multiple obesity and metabolic disease candidates using its RaniPill platform. The agreement focuses on preclinical development of RaniPill formulations for selected PegBio molecules, aiming to advance promising candidates into clinical development.MarketScreenerRani Therapeutics, PegBio Collaborate on Oral Delivery of Obesity DrugsRani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focusing on oral biologics, announced a collaboration with PegBio. The partnership aims to develop oral obesity drugs using Rani's proprietary RaniPill platform.Investing.comRani Therapeutics partners with PegBio on obesity drugs By Investing.comRani Therapeutics Holdings announced a research and development collaboration with PegBio Co., Ltd. to develop oral delivery formulations for obesity and metabolic disease molecules using Rani's RaniPill platform, with the goal of advancing candidates into clinical development. The collaboration expands Rani's obesity programs beyond its existing pipeline, which includes RT-114 in Phase 1 trials, while the company has reported 164% revenue growth despite its stock declining 48.67% year-to-date.